Evidence map›Paper›PMID 26161558›Full record

ArticlePLoS neglected tropical diseases2015

Elimination of Onchocerciasis from Mexico.

Mario A Rodríguez-Pérez, Nadia A Fernández-Santos, María E Orozco-Algarra, José A Rodríguez-Atanacio, Alfredo Domínguez-Vázquez, Kristel B Rodríguez-Morales, Olga Real-Najarro, Francisco G Prado-Velasco, Eddie W Cupp, Frank O Richards and 4 more

3 registry-linked trialsOpen access · goldAbstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03517462 nacompletednot on this mapstarted 2018, after this paper: background citation

Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2018 to 2019Enrolled231ConditionsOnchocerciasisArmsIvermectin 3Mg Tab
NCT04188301 phase2completednot on this mapstarted 2019, after this paper: background citation

Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2019 to 2022Enrolled154ConditionsOnchocerciasisArmsIVM w/ ALB, Single dose of IDA, Three daily doses of IDA
NCT06070116 phase2active not recruitingnot on this mapstarted 2024, after this paper: background citation

Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis

TypeinterventionalSponsorWashington University School of MedicineRan2024 to 2026Enrolled300ConditionsOnchocercal Subcutaneous Nodule, Onchocerciasis, Onchocerciasis, Ocular, Onchocerca InfectionArmsIvermectin w/ Albendazole, Ivermectin + Diethylcarbamazine + Albendazole, Moxidectin + Albendazole, Moxidectin + Diethylcarbamazine + Albendazole
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Onchocerciasis Elimination: Progress and Challenges.Research and reports in tropical medicine · 2020
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 4 countries.

Mario A Rodríguez-PérezCentro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, Tamaulipas, México.
Nadia A Fernández-SantosDirección General de Programas Preventivos, Centro Nacional de Programas Preventivos y Control de Enfermedades, Secretaría de Salud, Colonia Escandón, Delegación Miguel Hidalgo, Mexico City, México.
María E Orozco-AlgarraDirección General de Programas Preventivos, Centro Nacional de Programas Preventivos y Control de Enfermedades, Secretaría de Salud, Colonia Escandón, Delegación Miguel Hidalgo, Mexico City, México.
José A Rodríguez-AtanacioDirección General de Programas Preventivos, Centro Nacional de Programas Preventivos y Control de Enfermedades, Secretaría de Salud, Colonia Escandón, Delegación Miguel Hidalgo, Mexico City, México.
Alfredo Domínguez-VázquezOnchocerciasis Elimination Program for the Americas, Guatemala City, Guatemala.
Kristel B Rodríguez-MoralesCentro de Biotecnología Genómica, Instituto Politécnico Nacional, Reynosa, Tamaulipas, México.
Olga Real-NajarroConsejería de Educación, Madrid, España, Leganés, Madrid, Spain.
Francisco G Prado-VelascoPrograma de Eliminación de la Oncocercosis en Chiapas, Departamento de Prevención y Control de Enfermedades Transmitidas por Vector, Secretaría de Salud Unidad Administrativa, Tuxtla Gutiérrez, Chiapas, México.
Eddie W CuppDepartment of Entomology and Plant Pathology, Auburn University, Auburn, Alabama, United States of America.
Frank O RichardsRiver Blindness Program, Carter Center, Atlanta, Georgia, United States of America.
Hassan K HassanGlobal Health Infectious Disease Research Program, Department of Global Health,University of South Florida, Tampa, Florida, United States of America.
Jesús F González-RoldánDirección General de Programas Preventivos, Centro Nacional de Programas Preventivos y Control de Enfermedades, Secretaría de Salud, Colonia Escandón, Delegación Miguel Hidalgo, Mexico City, México.
Pablo A Kuri-MoralesSubsecretaría de Prevención y Promoción de la Salud, Secretaría de Salud, Colonia Juárez, Delegación Cuauhtémoc, México, D.F., México.
Thomas R UnnaschGlobal Health Infectious Disease Research Program, Department of Global Health,University of South Florida, Tampa, Florida, United States of America.
Secretaria de Salud · MXInstituto Politécnico Nacional · MXUniversity of South Florida · USAuburn University · USCarter Center · USConsejería de Educación de la Junta de Castilla y León · ESSecretaria de Salud · HN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMexico is one of the six countries formerly endemic for onchocerciasis in Latin America. Transmission has been interrupted in the three endemic foci of that country and mass drug distribution has ceased. Three years after mass drug distribution ended, post-treatment surveillance (PTS) surveys were undertaken which employed entomological indicators to check for transmission recrudescence. METHODOLOGY/PRINCIPAL

findingsIn-depth entomologic assessments were performed in 18 communities in the three endemic foci of Mexico. None of the 108,212 Simulium ochraceum s.l. collected from the three foci were found to contain parasite DNA when tested by polymerase chain reaction-enzyme-linked immunosorbent assay (PCR-ELISA), resulting in a maximum upper bound of the 95% confidence interval (95%-ULCI) of the infective rate in the vectors of 0.035/2,000 flies examined. This is an order of magnitude below the threshold of a 95%-ULCI of less than one infective fly per 2,000 flies tested, the current entomological criterion for interruption of transmission developed by the international community. The point estimate of seasonal transmission potential (STP) was zero, and the upper bound of the 95% confidence interval for the STP ranged from 1.2 to 1.7 L3/person/season in the different foci. This value is below all previous estimates for the minimum transmission potential required to maintain the parasite population. CONCLUSIONS/SIGNIFICANCE: The results from the in-depth entomological post treatment surveillance surveys strongly suggest that transmission has not resumed in the three foci of Mexico during the three years since the last distribution of ivermectin occurred; it was concluded that transmission remains undetectable without intervention, and Onchocerca volvulus has been eliminated from Mexico.

Indexed as

AnimalsAnthelminticsFemaleHumansInsect VectorsIvermectinMaleMexicoOnchocerca volvulusOnchocerciasisSimuliidaeAnthelminticsIvermectin

Identifiers

PMID26161558
PMCPMC4498594
OpenAlexW885727374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.